Identification of SARS-CoV RBD-targeting monoclonal antibodies with cross-reactive or neutralizing activity against SARS-CoV-2.

Identification of SARS-CoV RBD-targeting monoclonal antibodies with cross-reactive or neutralizing activity against SARS-CoV-2.

SARS-CoV-2-caused COVID-19 instances are rising globally, calling for growing efficient therapeutics to regulate the present pandemic. SARS-CoV-2 and SARS-CoV acknowledge angiotensin-converting enzyme 2 (ACE2) receptor through the receptor-binding area (RBD). Here, we recognized six SARS-CoV RBD-specific neutralizing monoclonal antibodies (nAbs) that cross-reacted with SARS-CoV-2 RBD, two of which, 18F3 and 7B11, neutralized SARS-CoV-2 an infection. …

Identification of SARS-CoV RBD-targeting monoclonal antibodies with cross-reactive or neutralizing activity against SARS-CoV-2. Read More ยป